INmune Bio Shares Plummet After $13M Direct Offering Prices
Inmune Bio shares plummet 15% after announcing a $13 million registered direct offering, with 2.3 million shares priced at...
Revolutionize Your Finance News Experience with MorningExpert!
🌟 Custom-Tailored News Just for You: Say goodbye to information overload. Our cutting-edge filtering technology curates your feed to perfection, delivering only the finance news that matches your interests and professional ambitions.
🔔 Flexible Updates, Your Way: How do you like your updates? Choose from instant app notifications, email digests, or captivating video summaries to stay informed on your own terms.
🎥 Engaging Video Summaries: Pressed for time? Let our expert anchors brief you with video summaries, giving you the essence of each news piece in minutes.
🚨 Personalized Alerts: Never miss out on what matters most. Set custom alarms for topics you’re passionate about, and be the first in the know.
📹 Create Your Own Video Content: Dive deeper into the topics that intrigue you with personalized videos. Generated on demand, these videos bring your chosen keywords or interests to life.
MorningExpert is more than a news app; it’s a dedicated companion for anyone passionate about finance. Whether you’re a seasoned professional, an avid enthusiast, or simply eager to stay updated with the finance world, our app ensures you’re always ahead of the curve.
With features designed to make staying informed effortless and enjoyable—such as custom alarms and on-demand video content—navigating the finance landscape has never been simpler or more tailored to your needs.
Transform the way you consume finance news. Download MorningExpert now and step into a world of precision-informed finance knowledge. Your next-level finance journey starts here!
acquisition adjusted earnings AI analysts apple artificial intelligence Bitcoin CEO China demand dividend Donald Trump Dow Jones Industrial Average earnings economy extreme event FactSet Federal Reserve fourth quarter growth guidance hamas inflation interest rates investment investors Israel Microsoft net income net profit Nvidia profit revenue revenue growth S&P 500 sales shareholders shares stock stock market stocks tesla third quarter Trump Wall Street
Inmune Bio shares plummet 15% after announcing a $13 million registered direct offering, with 2.3 million shares priced at...
INmune Bio has received clearance from the FDA to proceed with its Alzheimer's disease program. The company's Phase 2...
Elevai Labs shares have more than doubled after signing an exclusive licensing agreement with INmune Bio. The agreement allows...
Elevai Labs has signed an exclusive worldwide licensing agreement with INmune Bio, granting them the use of INmune Bio's...
Shares of INmune Bio, a Florida-based immunology company, dropped 14% after announcing that its Alzheimer's disease treatment study would...
INmune Bio's study on a treatment for Alzheimer's disease will remain on full clinical hold, despite addressing previous issues....